Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis
Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerabil...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 2004-06, Vol.45 (6), p.1219-1222 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1222 |
|---|---|
| container_issue | 6 |
| container_start_page | 1219 |
| container_title | Leukemia & lymphoma |
| container_volume | 45 |
| creator | Musto, Pellegrino Falcone, Antonietta Sanpaolo, Grazia Bodenizza, Carlo Perla, Gianni Minervini, Maria Marta Cascavilla, Nicola Dell'olio, Matteo La Sala, Antonio Mantuano, Saverio Melillo, Lorella Nobile, Michele Scalzulli, Potito Rosario Bisceglia, Michele Carella, Angelo Michele |
| description | Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients. |
| doi_str_mv | 10.1080/10428190310001641143 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66868258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66868258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1780fe1c3c148fbfd1be9ae64eab39a79e4f55bcfeb1a2f9dfd227cf03a6bc123</originalsourceid><addsrcrecordid>eNqFkctu1DAUhiMEoqXwBgh5hWAR8C2ehEURKtCpVATisrYc57hx5djB9lDlIXhnHGYkhIToyrfvfMc6f1U9JvgFwS1-STCnLekwIxhjIjghnN2pjgmmXU05ZnfXPad1YfhR9SCl68I1naD3qyPSMLGejqufW8gQwxV4sHlBwaDPkObgE6Ac0MWksvW2rz9AWpzKgJ6dO_sD9HNkPfpUHsHnhG5sHtF2mSFCSNaHebTOavRl8UMME7wqnrlcFLyIkQkRvV25K6T8sFrG3_2TTQ-re0a5BI8O60n17f27r2fb-vLj-cXZm8ta8w3PNdm02ADRTBPemt4MpIdOgeCgetapTQfcNE2vDfREUdMNZqB0ow1mSvSaUHZSPd175xi-7yBlOdmkwTnlIeySFKIVLW3aW0HSCS5Yu4J8D-oYUopg5BztpOIiCZZrXvJfeZWyJwf_rp9g-FN0CKgAr_eA9WVuk7oJ0Q0yq8WFaKLy2ibJbmlx-pdhBOXyqFUEeR120Zc5__-PvwCLvrpf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19646388</pqid></control><display><type>article</type><title>Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Musto, Pellegrino ; Falcone, Antonietta ; Sanpaolo, Grazia ; Bodenizza, Carlo ; Perla, Gianni ; Minervini, Maria Marta ; Cascavilla, Nicola ; Dell'olio, Matteo ; La Sala, Antonio ; Mantuano, Saverio ; Melillo, Lorella ; Nobile, Michele ; Scalzulli, Potito Rosario ; Bisceglia, Michele ; Carella, Angelo Michele</creator><creatorcontrib>Musto, Pellegrino ; Falcone, Antonietta ; Sanpaolo, Grazia ; Bodenizza, Carlo ; Perla, Gianni ; Minervini, Maria Marta ; Cascavilla, Nicola ; Dell'olio, Matteo ; La Sala, Antonio ; Mantuano, Saverio ; Melillo, Lorella ; Nobile, Michele ; Scalzulli, Potito Rosario ; Bisceglia, Michele ; Carella, Angelo Michele</creatorcontrib><description>Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428190310001641143</identifier><identifier>PMID: 15360005</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Benzamides ; Enzyme Inhibitors - therapeutic use ; Female ; Glivec ; HES ; Humans ; Hypereosinophilic syndrome ; Hypereosinophilic Syndrome - complications ; Hypereosinophilic Syndrome - drug therapy ; Hypereosinophilic Syndrome - pathology ; Imatinib ; Imatinib Mesylate ; Male ; Middle Aged ; PDGFRA ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - therapeutic use ; Remission Induction ; T-Lymphocytes - pathology ; Treatment Outcome ; Tyrosine kinase</subject><ispartof>Leukemia & lymphoma, 2004-06, Vol.45 (6), p.1219-1222</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1780fe1c3c148fbfd1be9ae64eab39a79e4f55bcfeb1a2f9dfd227cf03a6bc123</citedby><cites>FETCH-LOGICAL-c474t-1780fe1c3c148fbfd1be9ae64eab39a79e4f55bcfeb1a2f9dfd227cf03a6bc123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10428190310001641143$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10428190310001641143$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15360005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Musto, Pellegrino</creatorcontrib><creatorcontrib>Falcone, Antonietta</creatorcontrib><creatorcontrib>Sanpaolo, Grazia</creatorcontrib><creatorcontrib>Bodenizza, Carlo</creatorcontrib><creatorcontrib>Perla, Gianni</creatorcontrib><creatorcontrib>Minervini, Maria Marta</creatorcontrib><creatorcontrib>Cascavilla, Nicola</creatorcontrib><creatorcontrib>Dell'olio, Matteo</creatorcontrib><creatorcontrib>La Sala, Antonio</creatorcontrib><creatorcontrib>Mantuano, Saverio</creatorcontrib><creatorcontrib>Melillo, Lorella</creatorcontrib><creatorcontrib>Nobile, Michele</creatorcontrib><creatorcontrib>Scalzulli, Potito Rosario</creatorcontrib><creatorcontrib>Bisceglia, Michele</creatorcontrib><creatorcontrib>Carella, Angelo Michele</creatorcontrib><title>Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Glivec</subject><subject>HES</subject><subject>Humans</subject><subject>Hypereosinophilic syndrome</subject><subject>Hypereosinophilic Syndrome - complications</subject><subject>Hypereosinophilic Syndrome - drug therapy</subject><subject>Hypereosinophilic Syndrome - pathology</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>PDGFRA</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>T-Lymphocytes - pathology</subject><subject>Treatment Outcome</subject><subject>Tyrosine kinase</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1DAUhiMEoqXwBgh5hWAR8C2ehEURKtCpVATisrYc57hx5djB9lDlIXhnHGYkhIToyrfvfMc6f1U9JvgFwS1-STCnLekwIxhjIjghnN2pjgmmXU05ZnfXPad1YfhR9SCl68I1naD3qyPSMLGejqufW8gQwxV4sHlBwaDPkObgE6Ac0MWksvW2rz9AWpzKgJ6dO_sD9HNkPfpUHsHnhG5sHtF2mSFCSNaHebTOavRl8UMME7wqnrlcFLyIkQkRvV25K6T8sFrG3_2TTQ-re0a5BI8O60n17f27r2fb-vLj-cXZm8ta8w3PNdm02ADRTBPemt4MpIdOgeCgetapTQfcNE2vDfREUdMNZqB0ow1mSvSaUHZSPd175xi-7yBlOdmkwTnlIeySFKIVLW3aW0HSCS5Yu4J8D-oYUopg5BztpOIiCZZrXvJfeZWyJwf_rp9g-FN0CKgAr_eA9WVuk7oJ0Q0yq8WFaKLy2ibJbmlx-pdhBOXyqFUEeR120Zc5__-PvwCLvrpf</recordid><startdate>20040601</startdate><enddate>20040601</enddate><creator>Musto, Pellegrino</creator><creator>Falcone, Antonietta</creator><creator>Sanpaolo, Grazia</creator><creator>Bodenizza, Carlo</creator><creator>Perla, Gianni</creator><creator>Minervini, Maria Marta</creator><creator>Cascavilla, Nicola</creator><creator>Dell'olio, Matteo</creator><creator>La Sala, Antonio</creator><creator>Mantuano, Saverio</creator><creator>Melillo, Lorella</creator><creator>Nobile, Michele</creator><creator>Scalzulli, Potito Rosario</creator><creator>Bisceglia, Michele</creator><creator>Carella, Angelo Michele</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040601</creationdate><title>Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis</title><author>Musto, Pellegrino ; Falcone, Antonietta ; Sanpaolo, Grazia ; Bodenizza, Carlo ; Perla, Gianni ; Minervini, Maria Marta ; Cascavilla, Nicola ; Dell'olio, Matteo ; La Sala, Antonio ; Mantuano, Saverio ; Melillo, Lorella ; Nobile, Michele ; Scalzulli, Potito Rosario ; Bisceglia, Michele ; Carella, Angelo Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1780fe1c3c148fbfd1be9ae64eab39a79e4f55bcfeb1a2f9dfd227cf03a6bc123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Glivec</topic><topic>HES</topic><topic>Humans</topic><topic>Hypereosinophilic syndrome</topic><topic>Hypereosinophilic Syndrome - complications</topic><topic>Hypereosinophilic Syndrome - drug therapy</topic><topic>Hypereosinophilic Syndrome - pathology</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>PDGFRA</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>T-Lymphocytes - pathology</topic><topic>Treatment Outcome</topic><topic>Tyrosine kinase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Musto, Pellegrino</creatorcontrib><creatorcontrib>Falcone, Antonietta</creatorcontrib><creatorcontrib>Sanpaolo, Grazia</creatorcontrib><creatorcontrib>Bodenizza, Carlo</creatorcontrib><creatorcontrib>Perla, Gianni</creatorcontrib><creatorcontrib>Minervini, Maria Marta</creatorcontrib><creatorcontrib>Cascavilla, Nicola</creatorcontrib><creatorcontrib>Dell'olio, Matteo</creatorcontrib><creatorcontrib>La Sala, Antonio</creatorcontrib><creatorcontrib>Mantuano, Saverio</creatorcontrib><creatorcontrib>Melillo, Lorella</creatorcontrib><creatorcontrib>Nobile, Michele</creatorcontrib><creatorcontrib>Scalzulli, Potito Rosario</creatorcontrib><creatorcontrib>Bisceglia, Michele</creatorcontrib><creatorcontrib>Carella, Angelo Michele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Musto, Pellegrino</au><au>Falcone, Antonietta</au><au>Sanpaolo, Grazia</au><au>Bodenizza, Carlo</au><au>Perla, Gianni</au><au>Minervini, Maria Marta</au><au>Cascavilla, Nicola</au><au>Dell'olio, Matteo</au><au>La Sala, Antonio</au><au>Mantuano, Saverio</au><au>Melillo, Lorella</au><au>Nobile, Michele</au><au>Scalzulli, Potito Rosario</au><au>Bisceglia, Michele</au><au>Carella, Angelo Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2004-06-01</date><risdate>2004</risdate><volume>45</volume><issue>6</issue><spage>1219</spage><epage>1222</epage><pages>1219-1222</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>15360005</pmid><doi>10.1080/10428190310001641143</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2004-06, Vol.45 (6), p.1219-1222 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66868258 |
| source | Taylor & Francis; MEDLINE; Taylor & Francis Medical Library - CRKN |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Benzamides Enzyme Inhibitors - therapeutic use Female Glivec HES Humans Hypereosinophilic syndrome Hypereosinophilic Syndrome - complications Hypereosinophilic Syndrome - drug therapy Hypereosinophilic Syndrome - pathology Imatinib Imatinib Mesylate Male Middle Aged PDGFRA Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - therapeutic use Remission Induction T-Lymphocytes - pathology Treatment Outcome Tyrosine kinase |
| title | Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T05%3A22%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heterogeneity%20of%20Response%20to%20Imatinib-Mesylate%20(Glivec)%20in%20Patients%20with%20Hypereosinophilic%20Syndrome:%20Implications%20for%20Dosing%20and%20Pathogenesis&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Musto,%20Pellegrino&rft.date=2004-06-01&rft.volume=45&rft.issue=6&rft.spage=1219&rft.epage=1222&rft.pages=1219-1222&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428190310001641143&rft_dat=%3Cproquest_cross%3E66868258%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19646388&rft_id=info:pmid/15360005&rfr_iscdi=true |